Complete Response Letters See Uptick With US FDA's Thumbs Down For Waylivra
Executive Summary
In first half of 2018, CRLs were rarely issued for CDER-regulated novel agents, but FDA's rejection of Waylivra marks second in two weeks.
You may also be interested in...
Ionis 12-Month FCS Data Position Olezarsen For Near-Term Filing
Showing its antisense drug can reduce triglycerides and risk of acute pancreatitis in familial chylomicronemia syndrome, Ionis plans to file olezarsen for approval soon, hoping for accelerated approval.
What Else Analysts Want To Know About Phase III Data For TMC’s Inclisiran
Looking to be a game-changer with a highly effective LDL-C-lowering agent dosed twice annually, The Medicines Company says inclisiran met efficacy endpoints in a large Phase III study. But observers await fuller data, including safety details.
Akcea Expects Convenience Edge For Tegsedi, Despite Monitoring Requirements
Approved two months after Alnylam’s Onpattro, Tegsedi is priced almost identically in the same hATTR indication. Ionis affiliate Akcea hopes weekly subcutaneous administration will provide convenience benefit compared to I.V. Onpattro.